Last reviewed · How we verify
OPC-1085EL
OPC-1085EL is a selective serotonin 5-HT2C receptor agonist that promotes weight loss by increasing satiety and reducing appetite.
OPC-1085EL is a selective serotonin 5-HT2C receptor agonist that promotes weight loss by increasing satiety and reducing appetite. Used for Obesity or overweight with weight-related comorbidities.
At a glance
| Generic name | OPC-1085EL |
|---|---|
| Also known as | OPC-1085EL ophthalmic solution |
| Sponsor | Otsuka Beijing Research Institute |
| Drug class | 5-HT2C receptor agonist |
| Target | 5-HT2C receptor |
| Modality | Small molecule |
| Therapeutic area | Obesity/Metabolic Disease |
| Phase | Phase 3 |
Mechanism of action
The drug acts as a partial agonist at the 5-HT2C receptor, which is expressed on pro-opiomelanocortin (POMC) neurons in the hypothalamus. Activation of these neurons suppresses appetite and increases energy expenditure, leading to reduced caloric intake and body weight reduction. This mechanism is distinct from monoamine reuptake inhibitors and targets a specific pathway involved in appetite regulation.
Approved indications
- Obesity or overweight with weight-related comorbidities
Common side effects
- Nausea
- Headache
- Diarrhea
- Dizziness
Key clinical trials
- OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects (PHASE3)
- Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension (PHASE3)
- Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension (PHASE3)
- Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |